Final results of the TANIA randomized phase III trial of bevacizumab (BEV) after progression on 1st-line BEV therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

被引：0
|
作者：
Vrdoljak, E.
Marschner, N.
Zielinski, C.
Gligorov, J.
Cortes, J.
Puglisi, F.
Aapro, M.
Fallowfield, L.
Fontana, A.
Inbar, M.
Kahan, Z.
Welt, A.
Levy, C.
Brain, E.
Pivot, X.
Putzu, C.
Gonzalez-Martin, A.
Ebel, K.
Easton, V.
von Minckwitz, G.
机构：
[1] Ctr Oncol, Split, Croatia
[2] Outpatient Canc Ctr, Freiburg, Germany
[3] Med Univ Vienna, Ctr Comprehens Canc, Vienna, Austria
[4] CECOG, Vienna, Austria
[5] Hop Tenon, F-75970 Paris, France
[6] Vall dHebron Univ Hosp, Barcelona, Spain
[7] Univ Hosp Udine, Udine, Italy
[8] Clin Genolier, Inst Multidisciplinaire Oncol, Genolier, Switzerland
[9] Univ Sussex, Brighton & Sussex Med Sch, SHORE C, Falmer, England
[10] Univ Hosp Pisa, Ist Toscana Tumori, Pisa, Italy
[11] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel
[12] Univ Szeged, Szeged, Hungary
[13] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Essen, Germany
[14] Ctr Francois Baclesse, F-14021 Caen, France
[15] Hop Rene Huguenin, Inst Curie, St Cloud, France
[16] Univ Hosp Jean Minjoz, Besancon, France
[17] Univ Hosp Sassari, Sassari, Italy
[18] MD Anderson Canc Ctr, Madrid, Spain
[19] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
[20] Stamford Consultants AG, Basel, Switzerland
[21] German Breast Grp, Neu Isenburg, Germany
[22] Univ Womens Hosp, Frankfurt, Germany
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.SABCS15-P6-14-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-14-01
引用
收藏
页数：2
相关论文
共 50 条
  • [41] First-Line Bevacizumab (Bev) Combined With Paclitaxel (pac) In Older Patients (pts) Treated for HER2-Negative Metastatic Breast Cancer (mBC) in a Routine Oncology Practice Study
    Foerster, F.
    Aktas, B.
    Geberth, M.
    Tschechne, B.
    Schneeweiss, A.
    Salat, C.
    Tesch, H.
    Welslau, M.
    Schmidt, M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S351 - S352
  • [42] PACLITAXEL (P) AND BEVACIZUMAB (BEV), AS FIRST-LINE CHEMOTHERAPY, IN PATIENTS WITH HER2-NEGATIVE METASTATIC BREAST CANCER (MBC). THE HELLENIC COOPERATIVE ONCOLOGY GROUP EXPERIENCE WITH BIOMARKER EVALUATION
    Kourea, H. P.
    Koutras, A. K.
    Kotoula, V.
    Bobos, M.
    Fountzila, A. Kalogera
    Papazisis, K. T.
    Christodoulou, C.
    Res, E.
    Bournakis, E.
    Fountzilas, G.
    ANNALS OF ONCOLOGY, 2010, 21 : 104 - 104
  • [43] Plasma biomarker analysis in patients with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X)
    Lam, Siu W.
    Nota, Nienke M.
    de Groot, Steffen M.
    Jager, Agnes
    Bos, Monique M. E. M.
    Linn, Sabine C.
    van den Bosch, Joan
    Braun, Hans J.
    van der Velden, Ankie M. T.
    Los, Maartje
    Portielje, Johanneke E. A.
    Kroep, Judith R.
    Honkoop, Aafke H.
    Smorenburg, Carolien H.
    Tanis, Bea
    van Riel, Johanna M. G. H.
    Terwogt, Jetske M. Meerum
    den Boer, Marien O.
    Douma, Joep
    Jeurissen, Frank
    Berends, Johan
    van Tinteren, Harm
    Boven, Epie
    CANCER RESEARCH, 2015, 75
  • [44] Clinical Benefit Rate and Time to Response in RIBBON-1, a Randomized, Double-Blind, Phase III Trial of Chemotherapy with or without Bevacizumab (B) for the First-Line Treatment of HER2-Negative Locally Recurrent or Metastatic Breast Cancer (MBC).
    Robert, N.
    Dieras, V
    Glaspy, J.
    Brufsky, A.
    Bondarenko, I. N.
    Lipatov, O.
    Perez, E.
    Yardley, D.
    Phan, S-C
    Bhattacharya, S.
    O'Shaughnessy, J.
    CANCER RESEARCH, 2009, 69 (24) : 851S - 851S
  • [45] First-line bevacizumab plus paclitaxel in Japanese patients with HER2-negative metastatic breast cancer: subgroup results from the randomized Phase III MERiDiAN trial
    Masuda, Norikazu
    Takahashi, Masato
    Nakagami, Kazuhiko
    Okumura, Yasuhiro
    Nakayama, Takahiro
    Sato, Nobuaki
    Kanatani, Kazumitsu
    Tajima, Kosei
    Kashiwaba, Masahiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (05) : 385 - 392
  • [46] First-Line Bevacizumab (Bev) Combination Therapy in Triple-Negative (TN) Locally Recurrent/Metastatic Breast Cancer (LR/MBC): Subpopulation Analysis of Study MO19391 in >2000 Patients (Pts).
    Thomssen, C.
    Pierga, J-Y
    Pritchard, K., I
    Biganzoli, L.
    Cortes-Funes, H.
    Petrakova, K.
    Kaufman, B.
    Smith, I. E.
    CANCER RESEARCH, 2009, 69 (24) : 854S - 854S
  • [47] Randomized phase II study of weekly versus every-3-week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC)
    Rugo, H. S.
    Campone, M.
    Amadori, D.
    Wardley, A.
    Villa, E.
    Conte, P. F.
    Mudenda, B.
    McHenry, B.
    Pivot, X.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [48] Real-world effectiveness and safety of first-line bevacizumab (BEV) plus paclitaxel (PAC) in > 2000 patients (pts) with HER2-negative metastatic breast cancer (mBC)
    Mueller, V.
    Dank, M.
    de Ducla, S.
    Mitchell, L.
    Schneeweiss, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [49] Phase II study of gemcitabine (G) and bevacizumab (B) as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer (MBC)
    Borson, R.
    Harker, W. G.
    Reeves, J. E.
    Drosick, D.
    Beck, J. T.
    Hager, S. J.
    Horvath, W. L.
    Bromund, J.
    Zeigler, H.
    Tai, D.
    Yardley, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [50] Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study
    Dieras, Veronique
    Wildiers, Hans
    Jassem, Jacek
    Dirix, Luc Y.
    Guastalla, Jean-Paul
    Bono, Petri
    Hurvitz, Sara A.
    Goncalves, Anthony
    Romieu, Gilles
    Limentani, Steven A.
    Jerusalem, Guy
    Lakshmaiah, K. C.
    Roche, Henri
    Sanchez-Rovira, Pedro
    Pienkowski, Tadeusz
    Segui Palmer, Miguel Angel
    Li, Ai
    Sun, Yu-Nien
    Pickett, Cheryl A.
    Slamon, Dennis J.
    BREAST, 2015, 24 (03): : 182 - 190
12345